Quarterly report pursuant to Section 13 or 15(d)

Schedule of Effect of Restatement on Financial Statements (Details)

Schedule of Effect of Restatement on Financial Statements (Details) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,951,054						$ 13,951,054		$ 27,265,703
Other receivables									6,987
Prepaid expenses and other current assets	2,572,033						2,572,033		434,699
Total current assets	16,523,087						16,523,087		27,707,389
Property and equipment, net	132,382						132,382		45,708
Operating lease right-of-use assets	395,435						395,435		477,882
Total assets	17,050,904						17,050,904		28,230,979
Current liabilities:
Accounts payable and accrued expenses	946,084						946,084		947,574
Short-term notes payable	424,924						424,924		303,416
Operating lease liabilities	201,973						201,973		194,270
Total current liabilities	1,572,981						1,572,981		1,445,260
Long-term liabilities:
Operating lease liabilities	204,593						204,593		299,520
Total long-term liabilities	204,593						204,593		299,520
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000, and 9,417,000 Series A shares, 4,050,000 and 6,600,000 Series B shares, issued and outstanding at September 30, 2022 and December 31, 2021, respe	1,592,723						1,592,723		2,656,713
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively, 117,304,809 and 116,394,806 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	117,305						117,305		116,395
Additional paid-in capital	196,888,079						196,888,079		194,987,219
Accumulated deficit	(183,324,777)						(183,324,777)		(171,274,128)
Total shareholders’ equity	15,273,330	$ 18,674,898	$ 21,985,453	$ 28,546,423	$ 32,733,400	$ 36,050,467	15,273,330	$ 28,546,423	26,486,199	$ 16,844,595
Total liabilities and shareholders’ equity	17,050,904						17,050,904		$ 28,230,979
Grant revenue	86,047						131,521
Operating expenses:
Research and development	2,777,068			3,547,321			8,660,761	9,275,800
General and administrative	1,215,009			847,134			3,590,892	4,194,103
Total operating expenses	3,992,077			4,394,455			12,251,653	13,469,903
Loss from operations	(3,906,030)			(4,394,455)			(12,120,132)	(13,469,903)
Other income (expense):
Interest income	41,634			17,760			68,909	62,047
Interest expense	(5,228)			(7,053)			(9,290)	(10,654)
Local business tax	(489)						(1,469)
Miscellaneous income							11,333	670
Total other income, net	35,917			10,709			69,483	50,865
Loss before income taxes	(3,870,113)			(4,383,746)			(12,050,649)	(13,419,038)
Income tax benefit
Net loss	$ (3,870,113)	(3,589,543)	(4,590,993)	$ (4,383,746)	(3,815,347)	(5,219,945)	$ (12,050,649)	$ (13,419,038)
Basic and diluted net loss per share	$ (0.03)			$ (0.04)			$ (0.10)	$ (0.12)
Shares used to compute basic and diluted net loss per share	116,744,807			116,262,938			116,511,473	111,748,586
Cash flows from operating activities:
Net loss	$ (3,870,113)	$ (3,589,543)	(4,590,993)	$ (4,383,746)	$ (3,815,347)	(5,219,945)	$ (12,050,649)	$ (13,419,038)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization							31,594	34,817
Gain on sale of property and equipment							(10,964)
Stock-based compensation expense	468,545			100,769			837,780	1,455,670
Changes in operating assets and liabilities:
Other receivables							6,987
Prepaid expenses and other current assets							(1,608,905)	356,756
Accounts payable and accrued expenses							(1,490)	586,177
Net cash used in operating activities							(12,795,647)	(10,985,618)
Cash flows from investing activities:
Proceeds from sale of property and equipment							12,000
Purchase of property and equipment							(124,081)	(24,123)
Net cash used in investing activities							(112,081)	(24,123)
Cash flows from financing activities:
Payments on short-term notes payable							(406,921)	(346,138)
Redemption of Series C Preferred stock								(5,635,672)
Proceeds from issuance of common stock for option exercise								363,140
Proceeds from issuance of common stock for warrant exercise								2,261,336
Net proceeds from issuance of common stock								26,676,392
Net cash provided by financing activities							(406,921)	23,319,058
Net increase (decrease) in cash and cash equivalents							(13,314,649)	12,309,317
Cash and cash equivalents at beginning of period			27,265,703			$ 17,639,575	27,265,703	17,639,575
Cash and cash equivalents at end of period	13,951,054			$ 29,948,892			13,951,054	29,948,892
Supplemental disclosure of cash flow information:
Interest paid							9,290	10,654
Non-cash investing and financing activities:
Borrowings under short term notes payable for prepaid expense							528,429	600,169
Value of Series A preferred stock converted into common stock							415,169
Value of Series B preferred stock converted into common stock							648,821
Par value of common stock issued in connection with Series A Preferred Stock Conversion							400
Par value of common stock issued in connection with Series B Preferred Stock Conversion							510
Stock dividend on Series C Preferred stock
Previously Reported [Member]
Current assets:
Cash and cash equivalents	13,951,054						13,951,054
Other receivables
Prepaid expenses and other current assets	561,952						561,952
Total current assets	14,513,006						14,513,006
Property and equipment, net	132,382						132,382
Operating lease right-of-use assets	395,435						395,435
Total assets	15,040,823						15,040,823
Current liabilities:
Accounts payable and accrued expenses	871,084						871,084
Short-term notes payable	424,924						424,924
Operating lease liabilities	201,973						201,973
Total current liabilities	1,497,981						1,497,981
Long-term liabilities:
Operating lease liabilities	204,593						204,593
Total long-term liabilities	204,593						204,593
Shareholders’ equity:
Preferred stock, no par value; 50,000,000 shares authorized; 5,417,000, and 9,417,000 Series A shares, 4,050,000 and 6,600,000 Series B shares, issued and outstanding at September 30, 2022 and December 31, 2021, respe	1,592,723						1,592,723
Common stock, $0.001 par value; 250,000,000 and 200,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively, 117,304,809 and 116,394,806 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	117,305						117,305
Additional paid-in capital	196,888,079						196,888,079
Accumulated deficit	(185,259,858)						(185,259,858)
Total shareholders’ equity	13,338,249						13,338,249
Total liabilities and shareholders’ equity	15,040,823						15,040,823
Grant revenue	86,047						131,521
Operating expenses:
Research and development	2,824,598						10,595,842
General and administrative	1,215,009						3,590,892
Total operating expenses	4,039,607						14,186,734
Loss from operations	(3,953,560)						(14,055,213)
Other income (expense):
Interest income	41,634						68,909
Interest expense	(5,228)						(9,290)
Local business tax	(489)						(1,469)
Miscellaneous income							11,333
Total other income, net	35,917						69,483
Loss before income taxes	(3,917,643)						(13,985,730)
Income tax benefit
Net loss	$ (3,917,643)						$ (13,985,730)
Basic and diluted net loss per share	$ (0.03)						$ (0.12)
Shares used to compute basic and diluted net loss per share	116,744,807						116,511,473
Cash flows from operating activities:
Net loss	$ (3,917,643)						$ (13,985,730)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization							31,594
Gain on sale of property and equipment							(10,964)
Stock-based compensation expense							837,780
Changes in operating assets and liabilities:
Other receivables							6,987
Prepaid expenses and other current assets							401,176
Accounts payable and accrued expenses							(76,490)
Net cash used in operating activities							(12,795,647)
Cash flows from investing activities:
Proceeds from sale of property and equipment							12,000
Purchase of property and equipment							(124,081)
Net cash used in investing activities							(112,081)
Cash flows from financing activities:
Payments on short-term notes payable							(406,921)
Redemption of Series C Preferred stock
Proceeds from issuance of common stock for option exercise
Proceeds from issuance of common stock for warrant exercise
Net proceeds from issuance of common stock
Net cash provided by financing activities							(406,921)
Net increase (decrease) in cash and cash equivalents							(13,314,649)
Cash and cash equivalents at beginning of period			27,265,703				27,265,703
Cash and cash equivalents at end of period	13,951,054						13,951,054
Supplemental disclosure of cash flow information:
Interest paid							9,290
Non-cash investing and financing activities:
Borrowings under short term notes payable for prepaid expense							528,429
Value of Series A preferred stock converted into common stock							415,169
Value of Series B preferred stock converted into common stock							648,821
Par value of common stock issued in connection with Series A Preferred Stock Conversion							400
Par value of common stock issued in connection with Series B Preferred Stock Conversion							510
Stock dividend on Series C Preferred stock
Revision of Prior Period, Adjustment [Member]
Current assets:
Prepaid expenses and other current assets	2,010,081						2,010,081
Current liabilities:
Accounts payable and accrued expenses	75,000						75,000
Shareholders’ equity:
Accumulated deficit	1,935,081						1,935,081
Operating expenses:
Research and development	(47,530)						(1,935,081)
Other income (expense):
Net loss							1,935,081
Cash flows from operating activities:
Net loss							1,935,081
Changes in operating assets and liabilities:
Prepaid expenses and other current assets							(2,010,081)
Accounts payable and accrued expenses							75,000
Cash flows from financing activities:
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period